Seattle-based single-cell sequencing company Parse Biosciences has successfully raised $50 million through a Series C financing round, accompanied by a debt facility from Horizon Technology Finance. This new funding round, combined with previous investments, brings Parse Biosciences’ total funding to over $100 million. The company had previously closed a $41.5 million Series B financing round in early 2022.
Soleus Capital led the Series C round, with participation from both new and existing investors, including Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital.
Parse Biosciences, which originated as a spinout from the University of Washington in 2021, outlined its plans for the new funds. The company intends to utilize the capital to facilitate expansion, scale its operations to meet growing demand for its technology, and continue serving its academic, biotech, and pharmaceutical customers.
The firm’s single-cell sequencing portfolio encompasses various products, including Evercode Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, and CRISPR Detect. Additionally, Parse Biosciences provides data analysis solutions tailored for applications such as immune profiling and pooled CRISPR screens.
The company’s focus on single-cell sequencing technology positions it at the forefront of advancements in genomics and personalized medicine.
